{"id":548,"date":"2021-09-23T17:42:24","date_gmt":"2021-09-23T17:42:24","guid":{"rendered":"https:\/\/newsletters.aans.org\/tumor\/?page_id=548"},"modified":"2021-09-23T18:36:25","modified_gmt":"2021-09-23T18:36:25","slug":"clinical-trials-abtc","status":"publish","type":"page","link":"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/","title":{"rendered":"Clinical Trials-ABTC"},"content":{"rendered":"<p><strong>Clinical Trial Highlight: 08\/25\/2021<\/strong><\/p>\n<h3>ABTC -1801:\u00a0 BGB-290\u00a0and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1\/2 Mutations<\/h3>\n<h5>Brief Summary<\/h5>\n<p>This phase I\/II trial studies the side effects and how well\u00a0<strong>BGB-290<\/strong>\u00a0(a PARP Inhibitor) and temozolomide work in treating patients with gliomas (brain tumors) with IDH1\/2 mutations that have come back.\u00a0<strong>BGB-290<\/strong>\u00a0may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving\u00a0<strong>BGB-290<\/strong>\u00a0and temozolomide may work better in treating patients with recurrent gliomas.<\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2021\/09\/table.png\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-555\" src=\"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2021\/09\/table.png\" alt=\"\" width=\"1095\" height=\"738\" srcset=\"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2021\/09\/table.png 1095w, https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2021\/09\/table-300x202.png 300w, https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2021\/09\/table-1024x690.png 1024w, https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2021\/09\/table-768x518.png 768w\" sizes=\"auto, (max-width: 1095px) 100vw, 1095px\" \/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Clinical Trial Highlight: 08\/25\/2021 ABTC -1801:\u00a0 BGB-290\u00a0and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1\/2 Mutations Brief Summary This phase I\/II trial studies the side effects and how well\u00a0BGB-290\u00a0(a PARP Inhibitor) and temozolomide work in treating patients with gliomas (brain tumors) with IDH1\/2 mutations that have come back.\u00a0BGB-290\u00a0may stop the growth of tumor cells [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":555,"parent":455,"menu_order":13,"comment_status":"closed","ping_status":"closed","template":"NewsletterTOC.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-548","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Clinical Trials-ABTC - Tumor News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical Trials-ABTC - Tumor News\" \/>\n<meta property=\"og:description\" content=\"Clinical Trial Highlight: 08\/25\/2021 ABTC -1801:\u00a0 BGB-290\u00a0and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1\/2 Mutations Brief Summary This phase I\/II trial studies the side effects and how well\u00a0BGB-290\u00a0(a PARP Inhibitor) and temozolomide work in treating patients with gliomas (brain tumors) with IDH1\/2 mutations that have come back.\u00a0BGB-290\u00a0may stop the growth of tumor cells [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/\" \/>\n<meta property=\"og:site_name\" content=\"Tumor News\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-23T18:36:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2021\/09\/table.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1095\" \/>\n\t<meta property=\"og:image:height\" content=\"738\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2021\\\/clinical-trials-abtc\\\/\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2021\\\/clinical-trials-abtc\\\/\",\"name\":\"Clinical Trials-ABTC - Tumor News\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2021\\\/clinical-trials-abtc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2021\\\/clinical-trials-abtc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/newsletters.aans.org\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2021\\\/09\\\/table.png\",\"datePublished\":\"2021-09-23T17:42:24+00:00\",\"dateModified\":\"2021-09-23T18:36:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2021\\\/clinical-trials-abtc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2021\\\/clinical-trials-abtc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2021\\\/clinical-trials-abtc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2021\\\/09\\\/table.png\",\"contentUrl\":\"https:\\\/\\\/newsletters.aans.org\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2021\\\/09\\\/table.png\",\"width\":1095,\"height\":738},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2021\\\/clinical-trials-abtc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tumor News: Fall 2021\",\"item\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2021\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Clinical Trials-ABTC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#website\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/\",\"name\":\"Tumor News\",\"description\":\"Just another AANS Newsletter Sites site\",\"publisher\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#organization\",\"name\":\"Tumor News\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2024\\\/11\\\/JST.2024.logo_.png\",\"contentUrl\":\"https:\\\/\\\/newsletters.aans.org\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2024\\\/11\\\/JST.2024.logo_.png\",\"width\":2336,\"height\":2294,\"caption\":\"Tumor News\"},\"image\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical Trials-ABTC - Tumor News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/","og_locale":"en_US","og_type":"article","og_title":"Clinical Trials-ABTC - Tumor News","og_description":"Clinical Trial Highlight: 08\/25\/2021 ABTC -1801:\u00a0 BGB-290\u00a0and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1\/2 Mutations Brief Summary This phase I\/II trial studies the side effects and how well\u00a0BGB-290\u00a0(a PARP Inhibitor) and temozolomide work in treating patients with gliomas (brain tumors) with IDH1\/2 mutations that have come back.\u00a0BGB-290\u00a0may stop the growth of tumor cells [&hellip;]","og_url":"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/","og_site_name":"Tumor News","article_modified_time":"2021-09-23T18:36:25+00:00","og_image":[{"width":1095,"height":738,"url":"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2021\/09\/table.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/","url":"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/","name":"Clinical Trials-ABTC - Tumor News","isPartOf":{"@id":"https:\/\/newsletters.aans.org\/tumor\/#website"},"primaryImageOfPage":{"@id":"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/#primaryimage"},"image":{"@id":"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/#primaryimage"},"thumbnailUrl":"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2021\/09\/table.png","datePublished":"2021-09-23T17:42:24+00:00","dateModified":"2021-09-23T18:36:25+00:00","breadcrumb":{"@id":"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/#primaryimage","url":"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2021\/09\/table.png","contentUrl":"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2021\/09\/table.png","width":1095,"height":738},{"@type":"BreadcrumbList","@id":"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/clinical-trials-abtc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/newsletters.aans.org\/tumor\/"},{"@type":"ListItem","position":2,"name":"Tumor News: Fall 2021","item":"https:\/\/newsletters.aans.org\/tumor\/fall-2021\/"},{"@type":"ListItem","position":3,"name":"Clinical Trials-ABTC"}]},{"@type":"WebSite","@id":"https:\/\/newsletters.aans.org\/tumor\/#website","url":"https:\/\/newsletters.aans.org\/tumor\/","name":"Tumor News","description":"Just another AANS Newsletter Sites site","publisher":{"@id":"https:\/\/newsletters.aans.org\/tumor\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/newsletters.aans.org\/tumor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/newsletters.aans.org\/tumor\/#organization","name":"Tumor News","url":"https:\/\/newsletters.aans.org\/tumor\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/newsletters.aans.org\/tumor\/#\/schema\/logo\/image\/","url":"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2024\/11\/JST.2024.logo_.png","contentUrl":"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2024\/11\/JST.2024.logo_.png","width":2336,"height":2294,"caption":"Tumor News"},"image":{"@id":"https:\/\/newsletters.aans.org\/tumor\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/comments?post=548"}],"version-history":[{"count":6,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/548\/revisions"}],"predecessor-version":[{"id":556,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/548\/revisions\/556"}],"up":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/455"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/media\/555"}],"wp:attachment":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/media?parent=548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}